Email bulletins

Archive

August 2019

  • FDA warns of rare cases of serious liver injury with newer hepatitis C drugs
  • Voluntary licensing of hepatitis C drugs has led to more people on treatment
  • Late diagnosis of hepatitis C
  • Hepatitis B raises the risk of some cancers
  • Young adults with vertical HIV and hepatitis C co-infection have a high hepatitis C cure rate
  • 13% of HIV-positive Europeans who are cured of hepatitis C are reinfected
  • Statins linked to lower risk of liver cancer in people with hepatitis B or C
  • San Francisco sees new success in treating homeless people with hepatitis C
  • Is this your copy of the infohep news bulletin?

July 2019

  • WHO urges countries to invest in eliminating hepatitis
  • 15 million affected by hepatitis in Pakistan
  • World Hepatitis Day masterclasses
  • Treatment in primary care improves the uptake of treatment in people who inject drugs
  • UK Pharmacy Minister urged to allow pharmacist dispensing of DAAs
  • Heart disease and cancers in people with HIV and hepatitis C co-infection
  • Is this your copy of the infohep news bulletin?

June 2019

  • African hepatitis summit
  • Egypt to provide hepatitis C testing, treatment for 14 countries
  • Opioid substitution prescribers and DAA treatment
  • Pangenotypic treatment in France
  • How much can 'Netflix'-style pricing for hepatitis C drugs save?
  • Parkinson’s disease risk in people treated for hepatitis C
  • Hepatitis C stigma
  • Liver cancer screening
  • Hepatitis C vaccine not effective
  • Is this your copy of the infohep news bulletin?

May 2019

  • World Health Organization calls for greater focus on people who inject drugs in HCV treatment scale-up plans
  • Bulevirtide is a potential cure for hepatitis B and D
  • Is opt-out testing for HCV improving testing rates in UK prisons?
  • First paediatric pangenotypic treatment
  • NHS England strikes world leading deal to help eliminate hepatitis C
  • NHS England instructs GPs to do more hepatitis C testing after blood scandal
  • Is this your copy of the infohep news bulletin?

April 2019

  • News from The International Liver Congress, Vienna
  • Hepatitis C elimination by 2030 in doubt as countries fail to scale up diagnosis and treatment
  • 30 million screened for hepatitis C in four months in Egypt
  • Same-day diagnosis and treatment initiation for viral hepatitis
  • Hepatitis B cure strategy launched
  • Experimental hepatitis B drug produces deep and rapid decline in HBV DNA
  • Non-alcoholic fatty liver disease and NASH
  • NAFLD in people living with HIV
  • Simplified monitoring and highly effective treatment for hepatitis C
  • Tenofovir and liver cancer in HBV
  • Is this your copy of the infohep news bulletin?

March 2019

  • Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up
  • HCV reinfection in people who inject drugs a sign of a successful treatment programme, say researchers
  • US Department of Veterans Affairs on track to cure 100,000 of hepatitis C
  • Hepatitis C treatment reduces risk of diabetes
  • Hepatitis C treatment safe and effective in pregnant women, pilot study shows
  • Hepatitis B virus raises the risk of age-related macular degeneration
  • EndHep2030 call for proposals
  • World Hepatitis Alliance appoints new CEO and President
  • Next month: News from The International Liver Congress
  • Is this your copy of the infohep news bulletin?

February 2019

  • DAA treatment reduces the risk of death and liver cancer in France
  • Experimental therapy improves liver health in people with fatty liver disease
  • Immunotherapy combinations show promise for liver cancer
  • Generic treatment and hepatitis C elimination in Egypt
  • Hepatitis C cure does not improve long-term glucose control
  • Tackling HIV and hepatitis C in Europe: towards minimum standards
  • Improving the uptake of hepatitis C care in people who inject drugs
  • Is this your copy of the infohep news bulletin?

January 2019

  • Lancet Commission recommends actions to support elimination of hepatitis C
  • HCV modelling study
  • HIV/HCV co-infection and end-stage liver disease
  • Survival after liver cancer diagnosis is shorter in people living with HIV
  • Conditional cash transfers to encourage hepatitis C diagnosis and treatment in people who inject drugs
  • Barriers to HCV treatment in people who inject drugs
  • TAF for hepatitis B
  • AbbVie legal challenge in UK tender exercise dismissed
  • Is this your copy of the infohep news bulletin?
2019201820172016201520142013